Brentuximab vedotin is an antibody-drug conjugate and cytotoxic agent that selectively targets CD30-expressing cells to treat conditions such as relapsed or refractory Hodgkin lymphoma and systemic anaplastic… Read more
Brentuximab vedotin is an antibody-drug conjugate and cytotoxic agent that selectively targets CD30-expressing cells to treat conditions such as relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. This category offers high-quality reference standards for the parent drug, including its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. Pharmaceutical laboratories utilize these materials for essential analytical testing, method validation, and rigorous quality control processes. By employing these specific reference materials, researchers can conduct accurate impurity profiling and quantitation, ensuring the safety, efficacy, and consistency of the therapeutic agent throughout development and manufacturing. These compounds provide the necessary analytical support to maintain compliance with regulatory standards and facilitate reliable testing protocols for this complex biologic therapy.